What it's for (Indications)
- Mometasone furoate topical is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
- This includes conditions such as psoriasis, atopic dermatitis (eczema), and other inflammatory skin disorders where potent topical corticosteroid therapy is deemed appropriate by a healthcare professional.
- Its efficacy lies in reducing redness, swelling, itching, and discomfort associated with these dermatological conditions.
- The selection of mometasone furoate should be based on the severity and nature of the dermatosis, considering its classification as a high-potency topical corticosteroid, making it suitable for acute exacerbations or severe presentations of responsive conditions rather than long-term, continuous use without medical supervision.
- Careful diagnosis by a physician is essential before initiating treatment.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For adults and pediatric patients aged 2 years and older, a thin film of mometasone furoate topical cream, ointment, or lotion should be applied to the affected skin areas once daily. It is crucial to use the smallest amount necessary to cover the affected areas lightly. Treatment duration should be limited to the shortest possible time required to achieve therapeutic effect, typically not exceeding a few weeks, unless otherwise directed by a physician due to the potential for local and systemic adverse effects. Occlusive dressings should generally be avoided unless specifically instructed by a healthcare professional, as they can significantly increase systemic absorption. Discontinuation should be gradual after prolonged use to prevent rebound flares. This medication is for external dermatologic use only and should not be used on the face, groin, or axillae unless explicitly advised by a physician, nor should it be used ophthalmically, orally, or intravaginally. |
Safety & Warnings
Common Side Effects
- The most common local adverse reactions reported with mometasone furoate topical include burning, itching, stinging, and skin atrophy.
- Other local effects may comprise dryness, folliculitis, hypertrichosis (excessive hair growth), acneiform eruptions, hypopigmentation (lightening of the skin), perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, striae (stretch marks), and miliaria (prickly heat).
- These local reactions are more likely with prolonged use, under occlusive dressings, or on sensitive skin areas.
- Systemic absorption of topical corticosteroids can lead to reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria, particularly in patients treated over large surface areas, for prolonged periods, or with occlusive dressings.
- Pediatric patients are at higher risk for systemic toxicity.
- Ocular effects such as glaucoma and cataracts have been reported with the use of topical corticosteroids, especially with prolonged application near the eyes.
Serious Warnings
- Black Box Warning: While topical mometasone furoate does not carry a formal FDA-mandated Black Box Warning, healthcare professionals and patients must be fully aware of several serious potential risks associated with its use, particularly with prolonged application, high dosage, application to large body surface areas, or under occlusive dressings. These risks include the potential for hypothalamic-pituitary-adrenal (HPA) axis suppression, which can lead to adrenal insufficiency, a potentially life-threatening condition. Manifestations of Cushing's syndrome, hyperglycemia, and glucosuria have also been reported in susceptible individuals due to systemic absorption. Pediatric patients are particularly vulnerable to systemic toxicity due to a larger skin surface area to body weight ratio. Local adverse reactions, such as skin atrophy, striae, telangiectasias, and irreversible thinning of the skin, can occur with prolonged use, especially on sensitive areas like the face. Furthermore, topical corticosteroids may exacerbate or mask skin infections. Careful monitoring and adherence to prescribed duration and application instructions are paramount to minimize these serious risks.
- Patients should be advised to use mometasone furoate topical only as directed by their physician and not for any disorder other than for which it was prescribed.
- It is not for ophthalmic use.
- Systemic absorption of topical corticosteroids can produce reversible HPA axis suppression, potential manifestations of Cushing's syndrome, hyperglycemia, and glucosuria.
- Conditions that increase systemic absorption include the use of more potent steroids, prolonged use, application to large surface areas, and the use of occlusive dressings.
- Patients applying topical steroids to a large surface area or to areas under occlusion should be evaluated periodically for evidence of HPA axis suppression.
- If irritation, sensitization, or infection develops, treatment should be discontinued, and appropriate therapy instituted.
- Pediatric patients may demonstrate greater susceptibility to systemic toxicity due to a larger skin surface area to body weight ratio.
- Prolonged use on the face, scalp, groin, or axillae should be avoided due to increased risk of local adverse effects like atrophy.
- Pregnancy and lactation necessitate careful risk-benefit assessment, as corticosteroids are secreted in breast milk and can cross the placenta.
How it Works (Mechanism of Action)
Mometasone furoate is a synthetic, potent corticosteroid possessing anti-inflammatory, antipruritic, and vasoconstrictive properties. Its primary mechanism of action is thought to involve the induction of phospholipase A2 inhibitory proteins, collectively referred to as lipocortins. These proteins are responsible for controlling the biosynthesis of potent mediators of inflammation, such as prostaglandins and leukotrienes, by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. By inhibiting this enzymatic pathway, mometasone furoate effectively reduces the formation and release of these inflammatory mediators, thereby attenuating the inflammatory response. Furthermore, corticosteroids are known to exert immunosuppressive effects and possess anti-proliferative actions, contributing to their therapeutic benefits in various dermatoses. The vasoconstrictive action further aids in reducing erythema and edema at the site of application.